Reported 2 months ago
Amgen reported strong second-quarter revenues of $8.4 billion, exceeding expectations, with a 20% increase in sales despite lower net prices. CFO Peter Griffith highlighted that twelve of the company’s products showed double-digit growth and expressed confidence in continued demand for essential medicines, particularly in cardiovascular, bone, and asthma segments, even during economic downturns. Amgen has raised its guidance for the year, indicating robust prospects regardless of recession fears.
Source: YAHOO